Eric Carbonell
Psychiatry · Festus, MONPI 1801805791
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 61.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for psychiatry clinicians in MO, where the typical reported total is $226.
Across 2 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$25
- Sunovion Pharmaceuticals Inc.$16
Across 509 payments — averaging $10,529 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$2.2M
- Axsome Therapeutics, Inc.$1.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$973K
- Janssen Research & Development, LLC$330K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$262K
- AbbVie$257K
- plus $248K from 7 others
What the payments were for
- Food & beverage$41100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
How this compares
$41 in reported general payments places this provider in the 25th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $3,666 |
| Vilazodone Hcl | 16 | $1,720 |
| Clozapine | 14 | $1,643 |
| Paliperidone ErPaliperidone | 13 | $1,054 |
| Quetiapine Fumarate | 33 | $719 |
| Olanzapine | 30 | $686 |
| Buspirone Hcl | 23 | $608 |
| Aripiprazole | 17 | $470 |
| Benztropine Mesylate | 23 | $466 |
| Hydroxyzine Hcl | 18 | $447 |
| Haloperidol | 12 | $367 |
| Bupropion XlBupropion Hcl | 14 | $325 |
| Fluoxetine Hcl | 37 | $265 |
| Trazodone Hcl | 16 | $197 |
| Gabapentin | 12 | $188 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Festus
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.